rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TLSI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      TriSalus Life Sciences (TLSI) Stock Fair Value Moves Lower After Q3 Miss And Guidance Reset

      TriSalus Life Sciences is back in focus as analysts reset their fair value estimate from US$10 to US$8.25, reflecting a meaningful shift in how current upside is being framed. These changes follow recent Q3 results and a guidance reset, with research updates balancing concern around execution with interest in the TriNav platform and future procedure growth. As you read on, you will see how to track these evolving views and what to watch next in the TriSalus Life Sciences story. Stay updated...

      Nov 14Yahoo FinanceTLSI
      TriSalus at canaccord medtech forum: reset now, growth later
      Nov 11Investing.comTLSI
      TriSalus Life Sciences, Inc. Q3 2026 Earnings Call Summary
      Nov 10Yahoo FinanceTLSI
      TriSalus: 3 Key Takeaways for Long-Term Investors
      Nov 10Yahoo FinanceTLSI
      TriSalus stock price target lowered to $4 by Canaccord on guidance reset
      Nov 10Investing.comTLSI
      TriSalus Life Sciences Q3 Earnings Call Highlights
      Nov 10Yahoo FinanceTLSI
      TriSalus Life Sciences earnings missed by $0.03, revenue fell short of estimates
      Nov 10Investing.comTLSI
      TriSalus Life Sciences Q3 2026 Earnings Call Transcript
      Nov 10BenzingaTLSI
      Earnings to Watch: TriSalus Life Sciences Inc (TLSI) Q3 2026 -- GF Value Sees 57% Upside
      Nov 9Yahoo FinanceTLSI
      TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

      WESTMINSTER, Colo., October 29, 2026--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participat

      Oct 29Yahoo FinanceTLSI
      Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call - TriSalus Life Sciences (NASDAQ:TLSI)

      TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time

      Oct 12BenzingaTLSI
      TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support - TriSalus Life Sciences (NA

      TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.

      Sep 23BenzingaTLSI
      TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On

      U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.

      Sep 23BenzingaEDITTLSI
      TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance

      TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15. 6% in pre-market trading after the company announced that the U.

      Sep 23Yahoo FinanceTLSI
      H.C. Wainwright raises TriSalus stock price target on FDA approval
      Sep 23Investing.comTLSI
      Why is TriSalus Life Sciences stock surging today?
      Sep 23Investing.comTLSI
      Update: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
      Sep 23Yahoo FinanceTLSI
      TriSalus Life shares surge 29% on FDA device clearance
      Sep 22Investing.comTLSI
      TriSalus receives FDA clearance for TriNav Advance device
      Sep 22Investing.comTLSI
      TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

      WESTMINSTER, Colo., September 22, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio.

      Sep 22Yahoo FinanceTLSI
      TriSalus Life Sciences Gets FDA Clearance for TriNav Advance
      Sep 22Yahoo FinanceTLSI
      TriSalus at H.C. Wainwright conference: growth hinges on adoption
      Sep 14Investing.comTLSI
      TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

      WESTMINSTER, Colo., August 31, 2026--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

      Aug 31Yahoo FinanceTLSI

      This is the newest page. Registered accounts read further back.